Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study-Reference-Cited by-同舟云学术

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study

Published:2022-07-29 Issue:6 Volume:28 Page:1033-1043
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Kiialainen Anna¹^ORCID,Niggli Markus¹,Kempton Christine L.²^ORCID,Castaman Giancarlo³,Chang Tiffany⁴⁵,Paz‐Priel Ido⁴⁶,Adamkewicz Joanne I.⁴,Levy Gallia G.⁴⁵

Affiliation:

1. F. Hoffmann‐La Roche Ltd Basel Switzerland

2. Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory Emory University School of Medicine Atlanta Georgia USA

3. Center for Bleeding Disorders and Coagulation Careggi University Hospital Florence Italy

4. Genentech, Inc. South San Francisco California USA

5. Graphite Bio, Inc. South San Francisco California USA

6. Spark Therapeutics, Inc. Philadelphia Pennsylvania USA

Funder

F. Hoffmann-La Roche

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14642

Reference36 articles.

1. Social/economic costs and quality of life in patients with haemophilia in Europe

2. Monitoring joint health in haemophilia: Factors associated with deterioration

3. Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia

4. Decreased bone mineral density and associated factors in severe haemophilia A patients: A case‐control study

5. Bone mineral density in men and children with haemophilia A and B: a systematic review and meta-analysis

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab as a Promising Form of Therapy for Type A Hemophilia - AReview of Current Knowledge from Clinical Trials;Current Protein & Peptide Science;2024-11

2. Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies;Expert Review of Hematology;2024-09-12

3. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review;Research and Practice in Thrombosis and Haemostasis;2024-05

4. Haemophilic arthropathy: Diagnosis, management, and aging patient considerations;Haemophilia;2024-04

5. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B;Cochrane Database of Systematic Reviews;2024-02-27